Effect of policosanol on platelet aggregation and serum levels of arachidonic acid metabolites in healthy volunteers

Prostaglandins Leukotrienes and Essential Fatty Acids

Volumn 58, Issue 1, 1998, Pages 61-64

  Carbajal, D ^a   Arruzazabala, M L ^a   Valdes S ^a   Mas R ^a  

^a Center of Natural Products   (Cuba)

Author keywords

[No Author keywords available]

Indexed keywords

6 OXOPROSTAGLANDIN F1 ALPHA; ARACHIDONIC ACID DERIVATIVE; COLLAGEN; POLICOSANOL; PROSTACYCLIN; THROMBOXANE B2;

ADULT; ARACHIDONIC ACID METABOLISM; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG SCREENING; FEMALE; HUMAN; HUMAN EXPERIMENT; HYPERCHOLESTEROLEMIA; MALE; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; THROMBOCYTE AGGREGATION; THROMBOCYTE AGGREGATION INHIBITION;

EID: 0031962129     PISSN: 09523278     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0952-3278(98)90130-2     Document Type: Article

References (27)

1. Arruzazabala M. L., Carbajal D., Más R., Molina V., Valdés S., Laguna A. Cholesterol-lowering effects of policosanol in rabbits. Biological Research 1994; 27: 203-208.
2. Rodriguez-Echenique C., Mesa R., Mas R., Amor A. Y., Castaño G. Estudio del efecto sobre lípidos y lipoproteinas séricas y de la tolerancia al tratamiento oral con dosis crecientes de policosanol en monos Macaca arctoides. Archivos Venezolanos de Farmacologia y Terapéutica 1991; 11: 74-79.
3. Hernández F., Illnait J., Más R. et al. Effect of Ateromixol (policosanol) on serum lipids and lipoproteins in healthy volunteers. Current Therapeutic Research 1992; 51: 568-575.
4. Pons P., Más R., Illnait J. et al. Efficacy and safety of policosanol in patients with primary hypercholesterolemia. Current Therapeutic Research 1992; 52: 507-513.
5. Pons P., Jimenez A., Rodríguez M. et al. Effects of policosanol in elderly hypercholesterolemic patients. Current Therapeutic Research 1993; 53: 265-269.
6. Pons P., Rodríguez M., Robaina C. et al. Effects of policosanol successive dose increases on lipid profile of patients with type II hypercholesterolemia and tolerability to treatment. Int J Clin Pharmacol Res 1994; XIV: 27-33.
7. Aneiros E., Más R., Calderon B., Illnait J., Fernández L. Effects of policosanol in lowering-cholesterol levels in patients with type II hypercholesterolemia. Current Therapeutic Research 1995; 56: 176-182.
8. Castaño G., Zardoya R., Illnait J. et al. Efectos del tratamiento con Ateromixol (PPG) (5 mg) en pacientes con hiperlipoproteinemia tipo II. Progreso en Ciencias Médicas 1991; 5: 21-28.
9. Canetti M., Moreira M., Illnait J., Mas R., Fernández L., Castaño G. One year study on the effect of policosanol (5 mg twice a day) on lipid profile in patients with type II hypercholesterolemia. Advance Therapeutic 1995; 12: 245-254.
10. Torres O., Agramonte A. J., Illnait J., Más R., Fernández L., Fernández J. C. Treatment of hypercholesterolemia in NIDDM with policosanol. Diabetes Care 1995; 18: 393-397.
11. Arruzazabala M. L., Carbajal D., Más R., García M., Fraga V. Effects of policosanol on platelet aggregation in rats. Thrombosis Research 1993; 69: 321-327.
12. 2 Prostaglandins Leukot Essent Fatty Acids 1993; 49: 695-697.
13. Arruzazabala M. L., Carbajal D., Molina V., Valdés S., Más R., Garía M. Estudio farmacologico de la interaccion entre el policosanol y la aspirina en animales de experimentatión Revista. Iberoamericana de Trombosisy Hemostasia 1992; 5: 17-20.
14. Carbajal D., Arruzazabala M. L., Molina V., Más R. Effect of policosanol on experimental thrombosis models. Prostaglandins Leukot Essent Fatty Acids 1994; 50: 249-251.
15. Arruzazabala M. L., Valdés S., Más R., Fernández L., Carbajal D. Effect of policosanol successive dose increases on platelet aggregation in healthy volunteers. Pharmacological Research 1996; 33: 131-135.
16. Arruzazabala M. L., Valdés S., Mas R., Fernández L., Carbajal D. Effect of policosanol on platelet aggregation in healthy volunteers. XII International Symposium of Drug Affecting Lipid Metabolism. Houston, Texas, USA, 1995.
17. Scazziota A., Pons S., Altman R. Efecto del policosanol sobre la función plaquetaria en voluntarios sanos. Revista Iberoamericana de Trombosisy Hemostasia 1996; 9: 58-62.
18. Scazziota A., Pons S., Altman R. Effect of policosanol on platelet function in healthy volunteers. 14th International Congress on Thrombosis. Montpellier, France, 1996.
19. Born G. Aggregation of blood platelets by adenosine diphosphate and its reversal. Nature (Lond) 1962; 194: 927-929.
20. Hamberg M., Svensson J., Wakabayashi T., Samuelsson B. Isolation and structure of two prostaglandin endoperoxides that cause platelet aggregation. Proc Natl Acad Sci USA 1974; 71: 345-349.
21. Baumgartner H. R. Platelet interaction with collagen fibrils in flowing blood. I Reaction of human platelets with chymotrypsin-digested subendothelium. Thromb Haemost 1977; 37: 1-16.
22. Blackwell G. J., Duncombe W. G., Flower R. J., Parsons M. F., Vane J. R. The distribution and metabolism of arachidonic acid in rabbit platelets during aggregation and its modification by drugs. Br J Phannacol 1977; 59: 353-366.
23. Kennedy I., Coleman R. A., Humphrey P. P. A., Levy G. P., Lumpley P. Studies on the characterisation of prostanoid receptors: a proposed classification. Prostaglandins 1982: 24: 667-689.
24. Green K., Vesterqvist O. In vivo synthesis of thromboxane and prostacyclin in man in health and disease. Data from GC-MS measurements of major urinary metabolites. Adv Prostaglandin Thromboxane Leukot Res 1986; 16: 309-324.
25. 2 biosynthesis in human disease. Fed Proc 1987; 46: 154-158.
26. Catella F., Lawson J. A., Fitzgerald D. J., Fitzgerald G. A. Analysis of multiple thromboxane metabolites in plasma and urine. Adv Prostaglandin Thromboxane Leukot Res 1987; 17B: 611-614.
27. Roth G. J., Stanford N. S., Majerus P. W. Acetylation of prostaglandin synthetase by aspirin. Proc Natl Acad Sci USA 1975; 72: 3073-3076.